Telum Therapeutics Raises $19.2M for Hospital Infection Drugs

Jan de Vries · 2026-07-01

Telum Therapeutics, a Spanish BioTech company, just closed a massive Series A round to fight some of the nastiest bugs lurking in hospitals. We're talking about hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) – infections that can be deadly, especially for patients already fighting something else. The company raised about $19.2 million (that's €18 million converted). The round was led by the AMR Action Fund, with new investor Inveready jumping in, plus continued support from existing backers Invivo Partners, CDTI with its SICC Innvierte, Clave Capital, and Sodena. ### What's the Big Deal? Antimicrobial resistance (AMR) is one of those slow-moving crises that doesn't make headlines every day, but it's terrifying when you dig in. Bacteria are getting smarter than our antibiotics. Telum's approach is different – they're using their proprietary APEX platform to create protein-based antimicrobials that could outsmart these resistant bugs. Dr. Subhendu Basu, Telum's CEO, put it this way: "We are delighted to welcome AMR Action Fund and Inveready as new investors... AMR Action Fund's dedicated focus and deep expertise in antimicrobial resistance reinforces our confidence in the potential of the APEX platform." ### The Bigger Picture: European BioTech Funding Heats Up Telum's announcement isn't happening in a vacuum. There's been a wave of similar rounds across Europe this year. Here's a quick look at some comparable deals: - **mbiomics** (Bavaria, Germany): Raised $32.0 million (€30M) Series A for microbiome therapeutics targeting chronic and severe diseases. - **Generare** (Paris, France): Closed $21.3 million (€20M) Series A to expand its microbial-genome-based drug discovery platform. - **Helical** (London, UK): Raised $9.0 million (€8.4M) Seed round for AI infrastructure in pharma R&D. - **Gate2Brain** (Barcelona, Spain): Raised $7.5 million (€7M) to advance its brain tumor candidate and blood-brain barrier delivery platform. - **Avenue Biosciences** (Finland): Announced $5.1 million (€4.8M) Seed extension in January for protein engineering. Combined with Telum's round, that's roughly $94.0 million in disclosed 2026 funding across adjacent European BioTech, therapeutic platform, and drug discovery companies. Spain's Gate2Brain offers a nice same-country comparison. ### Telum's Lead Program: Targeting Acinetobacter baumannii Founded in 2019, Telum is zeroing in on Acinetobacter baumannii – a multidrug-resistant Gram-negative pathogen that's a nightmare in hospitals worldwide. It causes severe infections with high morbidity and mortality, especially in ICU patients on ventilators. Dr. Basu added: "This financing provides a clear path to complete Phase 1 development of our lead programme targeting Acinetobacter baumannii HABP/VABP, while also enabling us to advance our broader pipeline addressing both Gram-negative and Gram-positive pathogens." ### Why This Matters for Investors The AMR Action Fund isn't your typical VC. They're specifically focused on tackling antimicrobial resistance, which means they bring deep domain expertise and a long-term view. That's rare in BioTech, where many investors want quick exits. Dr. Henry Skinner, CEO of the AMR Action Fund, said: "Acinetobacter baumannii is one of the most formidable bacterial threats in modern medicine. It is clinically challenging, often resistant to first-line therapies, and a pathogen for which progress has been slow and difficult to achieve... We are encouraged by Telum's novel approach." ### What's Next? This $19.2 million injection gives Telum a clear runway to complete Phase 1 trials for their lead candidate. They'll generate critical safety and translational data that could unlock larger Phase 2 and 3 studies. If the APEX platform delivers, we could see a new class of antimicrobials that actually work against the toughest hospital infections. This financing brings together international and Spanish life sciences investors, tech-focused funds, and public institutions all committed to supporting innovation in health. It's a reminder that even in a tough funding environment, breakthrough science still attracts serious money.